Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients
Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
Deferasirox (DFX) is an oral iron chelator used to reduce iron overload (IO) caused by frequent blood cell transfusions in anemic myelodysplastic syndrome (MDS) patients. To study the molecular mechanisms by which DFX improves outcome in MDS, we analyzed the global gene expression in untreated MDS patients and those who were given DFX treatment. Th...
Alternative Titles
Full title
Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_4e59932ca0a745b3bfec0a888822a382
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_4e59932ca0a745b3bfec0a888822a382
Other Identifiers
ISSN
1424-8247
E-ISSN
1424-8247
DOI
10.3390/ph14010041
